Again, great post! This fits in with my feeling that August is when they would launch 9200 with a partner (as I've stated here previously). Hopefully, it'll all come together positively soon.
There is likely SOME distinction between the two.. maybe one is an isomer of the other.
I don't think they can be exact if they named differently..
I too think that they have good 8400 results in hand, and are trying to make deals for 9200.
(Though if I were a potential pharma partner, I would probably request to partner with 8400 instead. Why would I want to partner with 9200, of which little is known?? Give me the known stuff!... unless, of course, there's some special quality of 9200 which isn't public yet).
Interesting post. Quite suspicious.
Anyway, #1) yes, always have some cash on hand in case of a panic sell resulting in cheap shares, and
#2) don't count on sub $2.00 otherwise.
It's not that simple. ISR has product and sales. It's getting whacked today. Product and sales haven't helped AMRN or ARNA. KERX has done well primarily because they're an obvious buyout candidate. It's often about what Big Pharma wants. IDRA will do great if phase 2 does well in their trials.
Hey stayloose. Yes, my guess is that Excavater sold some or all this afternoon due to the bearish doji. Nothing wrong with that, as he prob hates to give back his profit. But who really knows what his deal is. Most here are looking for the big payout and aren't day traders. I myself want a core position at all times. Who knows when the big gap-up open will occur, such as when they announce a partnership for -9200.
BTW, regarding the FDA, any day now they are going to announce their decision on new expanded use for PGNX's drug. That's another big Baker Bros. holding. I put a few dollars into it last week. The BB have a good track record, like with CHTP, etc.
I try to look on the bright side. The longer it takes to really boom, the more likely I will have held over a year, so I'd have long- term capital gains tax instead of short-term. I just made 20%!!
Yeah, KERX has buyout written all over it, after approval. Easy call, probably the most sure thing in biotech right now.
Nah-- IDRA can soar long before the science is monetized. Most recent biotech buyouts have occurred well before monetization, some even only after phase 2. One great positive trial result this fall will start the ball rolling...people will see the massive market potential for 8400 and 9200 when they realize how broadly they might be used for a wide variety of autoimmune diseases in addition to those orphan diseases targeted in the trial.
..to force margin calls and pick up some cheap retail shares (from those who bought on margin this past week when ISR closed over the $3.00 minumum margin threshhold that most brokerages require).
I'm thinking we'll start our next leg up next week maybe thursday after some retailers have been squeezed..
..if the MM's let this close over $3.00 this week...
As discussed last night, I think they'll hold this below $3.00 a couple of more days to force margin sales and pick up cheap retail shares before letting the reigns go..
Lol. It happens with most biotechs....GALE, CYTR, ONCS....etc. Big sell-offs despite no bad news..
Anyway, I went off margin a couple of days ago....saw the writing on the wall when they pushed us under $3.00. I think the bottom is probably in or it's close, but they'll hold us under $3.00 for at least a few more days to force those margin calls and take shares. Fortunately, I sold other stuff and won't be giving away any of my IDRA shares at this low price.
Some of what you say is true...the 12 patient cohort results wont move the stock much. But some investors want that trial behind them before putting more money in, so it's still somewhat important. Additionally, they'll start IMO-9200 trial with a big pharma partner soon (July or Aug), which will cause a nice pop, and then continue to rise into the fall until orphan results (waldenstrom, etc)
Often, bad news is announced early, which catches investors off guard and holding the bag. I've seen good news announced late, as companies wait for the perfect time and/or partnerships.
Example: Keryx (KERX) announced bad news early (Perifosine failure), and good news late (Xerenex success).